ClinicalTrials.gg
Active, not recruitingNCT05711940Updated Aug 10, 2026

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

A Phase 3 interventional study of Psilocybin in Treatment Resistant Depression, sponsored by COMPASS Pathways. Active, not recruiting at 116 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by COMPASS Pathways · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
572
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant — 9 open to participants now, 14 under way, 2 of them phase 3. Psilocybin · Depressive Disorder, Treatment-Resistant.

Enrollment
Largest of 25
572 · median 30
Started
2023
with 2 others
Phase 3
3 of 25
none open now
Primary completion
2025-11
later than 2 of 13 live
Registered
12th of 25
by date
Lead sponsor
4 of 25
COMPASS Pathways

Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, this one has the largest enrollment, is one of 3 that started in 2023, is one of 3 in phase 3, reaches primary completion later than 2 of the 13 other live ones, and was the 12th registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

9 of the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, or all of them as a file.
02

Study summary

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Read the detailed description

This is a phase III, international, multi-centre, randomised, parallel group, fixed repeat dose, double-blind, controlled study. The study population will include participants aged ≥18 years with TRD.

Overall, 568 participants are to be randomised in a 2:1:1 ratio to receive COMP360 25 mg, 10 mg or 1 mg.

The study comprises three parts (A, B, and C) and will last approximately 62 weeks including a three- to ten-week screening period.

Part A will include a nine-week follow-up from initial investigational product (IP) administration.

Part B will include a further 17 weeks follow-up out to 26 weeks from initial IP administration.

Part C will include a further 26 weeks follow-up out to 52 weeks from initial IP administration.

In this study, the aim is to assess the efficacy of COMP360, administered with psychological support in adult participants with TRD, in improving symptoms of depression.

03

Conditions studied

  • Treatment Resistant Depression

Keywords

  • psilocybin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Aged ≥18 years at Screening
  2. Major depression without psychotic features (single or recurrent episode as informed by the , 5th edition [DSM-5])
  3. If the current major depressive episode is the participant's first lifetime episode of depression, the length of the current episode must be ≥3 months and ≤2 years at Screening
  4. MADRS total score ≥20 at Screening and Baseline to ensure at least moderate severity of depression
  5. TRD, defined as failure to respond to an adequate dose and duration of two, three, or four different pharmacological treatments for the current episode as determined through the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and using the supplementary advice on additional antidepressants not included in MGH-ATRQ
  6. At Screening, agreement to discontinue all prohibited medications

Key Exclusion Criteria:

  1. Prior or ongoing bipolar disorder, any psychotic disorder, including schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder (unless substance induced or due to a medical condition), antisocial personality disorder as assessed by a structured clinical interview (MINI 7.0.2)
  2. Lifetime paranoid, schizoid, schizotypal, histrionic, narcissistic personality disorder, or any ongoing serious psychiatric comorbidity based on medical history and clinical judgement
  3. Borderline personality disorder as demonstrated by medical history or the Mini International Neuropsychiatric Interview Plus (MINI plus) - borderline personality disorder module
  4. Ongoing post-traumatic stress disorder, obsessive-compulsive disorder, or anorexia nervosa as assessed by medical history and a structured clinical interview (MINI 7.0.2)
  5. Psychiatric inpatient within the past 12 months prior to Screening
  6. Use of electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation during the current depressive episode
  7. Transcranial magnetic stimulation within the past six months prior to Screening
  8. Current enrolment in a psychological therapy programme that will not remain stable for the duration of the study. Psychological therapies cannot have been initiated within 30 days prior to Screening
  9. Exposure to COMP360 psilocybin therapy prior to Screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
572 participants (actual)

Study arms

  • Experimental
    25 mg COMP360 Psilocybin

    25 mg COMP360 Psilocybin

    Drug: Psilocybin

  • Experimental
    10 mg COMP360 Psilocybin

    10 mg COMP360 Psilocybin

    Drug: Psilocybin

  • Active comparator
    1 mg COMP360 Psilocybin

    1 mg COMP360 Psilocybin, active comparator

    Drug: Psilocybin

Interventions

  • COMP360 Psilocybin administered under supportive conditions

    Also known as: COMP360

06

What researchers measure

Primary outcomes

  1. COMP360 25 mg versus COMP360 1 mg for the change from baseline in MADRS total score.

    Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity

    Time frame: Week 6

Secondary outcomes

  1. COMP360 25 mg versus COMP360 1 mg for the change from baseline in Sheehan Disability Scale (SDS) total score.

    Sheehan Disability Scale (SDS) is a brief, five-item self report inventory that assesses functional impairment in work/school, social life, and family life.

    Time frame: Week 6

  2. COMP360 25 mg versus COMP360 10 mg for the change from baseline in MADRS total score.

    Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity

    Time frame: Week 6

  3. COMP360 25 mg versus COMP360 10 mg for the change from baseline in Sheehan Disability Scale (SDS) total score.

    Sheehan Disability Scale (SDS) is a brief, five-item self report inventory that assesses functional impairment in work/school, social life, and family life.

    Time frame: Week 6

07

Study locations

116 sites

Showing the first 100 of 116 sites across 12 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Nov 2025, 32 months.

Of 24 phase 3 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 32 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2023
First posted
Feb 3, 2023
StartActual
Feb 14, 2023
Primary completionActual
Nov 13, 2025
CompletionEst.
Dec 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05711940
Lead sponsor
COMPASS Pathways
Responsible party
Sponsor
First posted
Feb 3, 2023
Start date
Feb 14, 2023
Primary completion
Nov 13, 2025
Completion
Dec 2026 (estimated)
Last update
Aug 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion